34th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220265693 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS - Hematopoietic stem cell (HSC) transplantation is a promising treatment for patients with various hematological diseases, immunodeficiency, autoimmune disorders, and other genetic disorders. Considerable work continues to strive toward the identification of critical factors involved in the successful engraftment and reconstitution of HSC recipients. The identification of these critical components and the understanding of how they may be therapeutically targeted would result in improved patient survival. E-selectin inhibitors for use in increasing survival of individuals that receive HSC transplantation or for reconstitution of depleted and compromised bone marrow are disclosed. | 2022-08-25 |
20220265694 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION - A compounded composition may include one or more active agents including betamethasone and one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The composition may be formulated by mixing dry powder including the active agents with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection. | 2022-08-25 |
20220265695 | OPTHALMIC COMPOSITIONS COMPRISING VISCOSIFYING POLYMERS AND NUCLEIC ACIDS - The invention relates to ophthalmic compositions comprising: i) a nucleic acid molecule, preferably an antisense oligonucleotide, such as an single-stranded antisense oligonucleotide that modulates splice modulation or prevention of RNA toxicity due to trinucleotide repeats in a target RNA molecule, or a gapmer that induces breakdown of a target RNA molecule after formation of a double-stranded RNA/gapmer complex; and ii) a viscosifying polymer. The ophthalmic compositions are for topical administration in the eye of a mammalian subject suffering from a corneal disease, such as a hereditary corneal dystrophy. The viscosifying polymer in the compositions of the invention allows the entry of the nucleic acid molecule to the different layers of the cornea: the corneal epithelium, Bowman's membrane, stroma, Dua's layer, the Descemet's membrane and/or the corneal endothelium. | 2022-08-25 |
20220265696 | MICRO-RNAS AND COMPOSITIONS COMPRISING SAME FOR THE TREATMENT AND DIAGNOSIS OF SEROTONIN-, ADRENALIN-, NORADRENALIN-, GLUTAMATE-, AND CORTICOTROPIN-RELEASING HORMONE- ASSOCIATED MEDICAL CONDITIONS - microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided. | 2022-08-25 |
20220265697 | -GLUCAN COMPOSITION AND USE THEREFOR - A β-glucan composition and use thereof. Specifically provided are uses of the β-glucan composition in preparing a composition for improving or treating immune-related diseases, said β-glucan being a β-glucan containing β-1,3 and β-1,6 glucosidic bonds in the molecules thereof, and having a molecular weight of 1-50 kDa. The β-glucan features a novel structure, a controllable mass, abundant sources, simple preparation processing, high product purity, strong biological activity, and is easy to produce industrially, among other strengths. The resulting water soluble β-glucan composition features better antitumor activity, has the potential to be developed into a safe and effective novel drug for improving or treating immune-related diseases and fighting tumors. | 2022-08-25 |
20220265698 | COMPOSITION FOR ENHANCING EFFECT OF ANTIBODY DRUG - Provided is a composition capable of enhancing the effect of an antibody drug such as an immune checkpoint inhibitor, etc. A β-glucan is used as an active ingredient of a composition for enhancing the effect of an antibody drug. This composition is used suitably for antibody drugs that have an effect of suppressing growth of cancer via immune checkpoint inhibition; e.g., antibody drugs including a monoclonal antibody to PD-L1. | 2022-08-25 |
20220265699 | HEPARAN SULFATE (HS) OLIGOSACCHARIDES EFFECT IN LIVER ISCHEMIA REPERFUSION INJURY - Disclosed is a method of treating liver ischemia reperfusion (I/R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I/R injury or at risk of suffering liver I/R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units. | 2022-08-25 |
20220265700 | METHODS TO PREVENT, INHIBIT OR TREAT INTERVERTEBRAL DISC DEGENERATION - A method to prevent, inhibit or treat intervertebral disc disease in a mammal and compositions useful in that regard are provided. | 2022-08-25 |
20220265701 | LIQUID COMPOSITION FOR USE IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX - The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of | 2022-08-25 |
20220265702 | COMBINATION THERAPIES THAT ENHANCE ANTIMICROBIAL/ANTICANCER ACTIVITIES - Techniques regarding a chemical composition that can be utilized within one or more combination therapies to treat a microbial infection are provided. For example, one or more embodiments described herein can comprise a chemical composition that includes a first triblock polymer comprising a quaternary ammonium functionalized polycarbonate block and exhibiting anticancer activity via a lytic mechanism. The chemical composition can also include a second triblock polymer comprising a guanidinium functionalized polycarbonate block and exhibiting anticancer activity via a translocation mechanism. | 2022-08-25 |
20220265703 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE - The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders. | 2022-08-25 |
20220265704 | TREATMENT OF AUTISM AND AUTISM SPECTRUM DISORDERS WITH BIOTIN COMPOSITIONS - The present application relates to the treatment of autism and autism spectrum disorders using biotin compositions. | 2022-08-25 |
20220265705 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF - A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to decrease muscle fatigue in an individual who participates in at least one of 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise. Preferably, the combination of calcium and at least one of oleuropein or metabolite thereof is administered to the individual less than two hours before the exercise, and/or during the exercise, and/or less than two hours after the exercise. | 2022-08-25 |
20220265706 | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEXES OF ALLOFERON AND ZINC - A composition containing biologically active complexes of zinc and the oligopeptide alloferon. A pharmaceutical composition with antiviral and immunomodulatory activity, the active ingredient is a mixture of biologically active complex compounds formed by the reaction of the oligopeptide alloferon with zinc ions in an aqueous medium, zinc and alloferon in solution form complex compounds having different compositions, and the concentration of the solutions of alloferon and a zinc salt is selected that the molar ratio of the components alloferon and zinc salt is from 1:1 to 1:2. A method for producing a pharmaceutical composition having zinc salt and alloferon dissolved separately in equal volumes of 0.9% solutions of sodium chloride or sodium acetate, mixed and pH is adjusted to 6.5-8.0. The composition, the contents and properties of which make it possible to achieve in solution a high concentration of complex compounds formed by the reaction of alloferon with zinc ions. | 2022-08-25 |
20220265707 | ANTIMICROBIAL NANO-SURFACTANT AND METHODS - An antimicrobial composition of buckminsterfullerene with saponified phosphorus acid functional groups is provided to disassemble or make virus particles inert, and to inhibit viral and fungal proteases using catalytic desulfurization. This composition is formulated to prevent or to treat novel corona viruses including emerging strains of SARS-Cov-2, as well as fungal pathologies such as valley fever and respiratory ailments such as chronic obstructive pulmonary disorder (COPD) and pneumonia. Virus particles are implicated in the development of cancers. The antiviral properties further enable the composition to prevent conditions leading to uncontrolled cellular proliferation, neoplasms, degenerative malignancy, and to help treat chronic inflammatory diseases associated with or leading to induce cancer in virus infected cells. The composition can be produced at low temperatures through reactive shear mixing. Delivery methods include ingestion, topical application, inhalation, or injection when used as a medicament or as a food supplement. | 2022-08-25 |
20220265708 | Modified Cell Expansion and Uses Thereof - The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell. | 2022-08-25 |
20220265709 | ENGINEERED CELLS AND USES THEREOF - A system for inducing activity of immune cells, comprises a chimeric antigen receptor, a T cell receptor, and various combinations thereof. | 2022-08-25 |
20220265710 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA - Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10 | 2022-08-25 |
20220265711 | ENGINEERED IMMUNE CELLS COMPRISING A RECOGNITION MOLECULE - Provided is an engineered immune cell comprising on its surface a recognition molecule that comprises a binding moiety specifically binding to a target molecule on the surface of a target cell, wherein the target molecule comprises an extracellular domain, and wherein the immune cell is capable of killing a target cell that comprises on its surface the target molecule. In one aspect, the binding moiety specifically binds to a distal portion of the extracellular domain, and the immune cell is capable of killing a target cell that comprises on its surface both the target molecule and the recognition molecule. In another aspect, the binding moiety specifically binds to a proximal portion of the extracellular domain, and the engineered immune cell has no or reduced capability of killing a target cell comprising on its surface both the target molecule and the recognition molecule. | 2022-08-25 |
20220265712 | POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS - Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of CYNK cells to the subject so as thereby to provide an effective treatment of the cancer in the subject. The CYNK cells can be placental-derived natural killer (NK) cells or placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and acute myeloid leukemia. The present invention also provides compositions comprising CYNK cells for the treatment of multiple myeloma and acute myeloid leukemia and methods of their use. | 2022-08-25 |
20220265713 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS - The present invention relates to a substance of formula (I), whereby R | 2022-08-25 |
20220265714 | METHOD FOR PRODUCING CELL POPULATION CONTAINING CAR-EXPRESSING IMMUNE CELLS - The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen. | 2022-08-25 |
20220265715 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF - Described herein are chimeric antigen receptors (CARs) comprising an extracellular target-binding domain comprising an antibody moiety (e.g., a single chain variable fragment (scFv) antibody), a transmembrane domain, a CD30 costimulatory domain, and a primary signaling domain. Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers). | 2022-08-25 |
20220265716 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS - Provided herein are pharmaceutical compositions, comprising a pharmaceutically acceptable carrier and therapeutically effective amounts of high affinity Natural Killer (haNK) cells and a therapeutic antibody in the form of a combined preparation. Also provided herein are methods for treating cancer by using the pharmaceutical composition comprising the haNK cells and the therapeutic antibody. | 2022-08-25 |
20220265717 | ANTIGEN RECEPTOR - A novel antigen receptor is provided. An antigen receptor contains a GITRL domain at a position closer to the C-terminus via a self-cleaving peptide domain. | 2022-08-25 |
20220265718 | IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS - Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells. | 2022-08-25 |
20220265719 | IMMUNOTHERAPIES - The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade). | 2022-08-25 |
20220265720 | METHODS FOR STEM CELL TRANSPLANTATION - The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of γδ T cell expansion and as T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD. | 2022-08-25 |
20220265721 | TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T CELLS - The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient. | 2022-08-25 |
20220265722 | ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLEY ISOLATED CELLS - The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing. | 2022-08-25 |
20220265723 | NON-VIRAL MODIFICATION OF MESENCHYMAL STEM CELLS - Described herein are methods for transfecting mesenchymal stem cells (MSCs) with a nucleic acid construct using a cationic polymer, a first reagent capable of redirecting endocytosed nucleic acids from intracellular acidic compartments, and a second agent capable of stabilizing a microtubular network of the MSCs. The methods are free of virus-based transfection vehicle materials and the transfected MSCs have substantially unchanged multipotent phenotype. In certain embodiments, the transfected MSCs express functional genes comprising suicide gene, such as cytosine deaminase or uracil phosphoribosyltransferase. Also described are methods for the treatment of diseases, such as cancer, using such transfected cells in combination with 5FC, 5FU, GCV, as well as kits and composition relating thereof. | 2022-08-25 |
20220265724 | CELL THERAPEUTIC AGENT FOR ANTI-INFLAMMATORY OR DAMAGED TISSUE REGENERATION COMPRISING PRUSSIAN BLUE NANOPARTICLES, AND METHOD FOR PREPARING THE SAME - An embodiment of the present invention provides a cell therapeutic agent for anti-inflammatory or damaged tissue regeneration comprising Prussian blue nanoparticles and cells, and a method for preparing the same. According to an embodiment of the present invention, there is an effect capable of providing a cell therapeutic agent having improved therapeutic performance and improved oxidative stress resistance, engraftment rate and viability at a damage site through the introduction of Prussian blue nanoparticles having ROS scavenging ability and anti-inflammatory properties, and a method for preparing the same. | 2022-08-25 |
20220265725 | USE OF VETO CELLS IN TREATMENT OF T CELL MEDIATED AUTOIMMUNE DISEASES - A method of treating or preventing a T cell mediated autoimmune disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation. | 2022-08-25 |
20220265726 | USE OF VETO CELLS FOR THE TREATMENT OF SICKLE CELL DISEASE - A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation. | 2022-08-25 |
20220265727 | IMMORTALIZED MYOBLAST CELL LINES AND USES THEREOF - The present invention relates to immortalized human cells particularly useful for cell encapsulation therapy and methods of preparation and use thereof. | 2022-08-25 |
20220265728 | PARTHENOGENIC ACTIVATION OF HUMAN OOCYTES FOR THE PRODUCTION OF HUMAN EMBRYONIC STEM CELLS - Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O | 2022-08-25 |
20220265729 | USE OF CELL WALL SKELETON OF ISOLATED RHODOCOCCUS RUBER FOR PREPARING HUMAN PAPILLOMAVIRUS INFECTION TREATMENT DRUG - Disclosed is a use of a cell wall skeleton of isolated | 2022-08-25 |
20220265730 | Engineered Bacteria Containing Biosensors for Precision Targeting and Containment - The disclosure herein relates to engineered biosensor-containing bacteria, which is bacteria that contain at least one biosensor circuit, and uses thereof. A biosensor circuit can comprise an essential gene of the bacteria operably linked to an inducible promoter. Additionally, the bacteria can be engineered to be deficient in the endogenous copy of the at least one essential gene. | 2022-08-25 |
20220265731 | MODIFIED ESCHERICHIA COLI STRAIN NISSLE AND TREATMENT OF GASTROINTESTINAL DISORDER - The invention relates to the field of modified | 2022-08-25 |
20220265732 | COMPOSITIONS AND METHODS FOR BROILER HEALTH AND PERFORMANCE - The disclosure relates to compositions and methods for improving broiler health and performance. Specifically, the disclosure provides compositions comprising one or more bacteria that can be administered to broilers to increase feed efficiency, weight gain, and immunity, and reduce or prevent inflammation, mortality, and/or the colonization of pathogenic microbes. | 2022-08-25 |
20220265733 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides pharmaceutical compositions comprising bacteria and the use of such compositions in the treatment of disease. | 2022-08-25 |
20220265734 | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATING OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL DISEASE - Disclosed herein, are compositions comprising a consortium of Clostridia, and methods of treating obesity, metabolic syndrome, irritable bowel disease, as well as reducing weight gain and inhibiting lipid absorption in the small intestine by administering the compositions to a subject. | 2022-08-25 |
20220265735 | CANINE MICROBE PREPARATIONS FOR INCREASING OXYTOCIN - The inventions disclosed herein relate to the findings that | 2022-08-25 |
20220265736 | PROBIOTIC COMPOSITION INCLUDING LACTIC ACID BACTERIAL STRAINS AND USE OF AT LEAST ONE OF SUCH STRAINS - Disclosed herein is a probiotic composition including | 2022-08-25 |
20220265737 | COMPOSITION FOR MAINTENANCE AND/OR IMPROVEMENT OF MEMORY/LEARNING ABILITY, AND FOOD, MEDICINE AND FEED EACH CONTAINING SAID COMPOSITION - A medicine, a food or a drink and feed which are effective for preventing and/or improving decline, occurring with age (senescence), in memory and learning ability are provided. A novel microorganism having the effect of preventing and/or improving decline, occurring with age (senescence,) in memory and learning ability is provided. More specifically, the microorganism is characterized by being a microorganism belonging to | 2022-08-25 |
20220265738 | SALUTARY EFFECTS OF INDIGENOUS PROBIOTICS AND NANOAEROSOL METHODS TO MITIGATE MICROBIAL INFECTIONS INCLUDING COVID 19 - Provided herein are materials and methods for the treatment of conditions associated with microbial infections including viral and bacterial infections in subjects in need thereof. In particular, provided herein are methods and compositions for treating viral infections, and in particular SARS-CoV-2 infections, in a subject in need thereof, where the methods comprise administering therapeutically effective amounts of indigenous lactic acid bacteria, such as the | 2022-08-25 |
20220265739 | Bacteriophage Hydrogel Compositions and Uses Thereof - Described herein are hydrogel compositions comprising cross-linked bacteriophages. The hydrogels are typically bioactive, degradable, for example biodegradable, self-healing, fluorescent, for example autofluorescent, and/or birefringent. The hydrogels described herein may be used as therapeutics or diagnostics, as scaffolds for material synthesis, as catalysts, as membranes or filters, or as biosensor substrates, for example. | 2022-08-25 |
20220265740 | TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT - The present disclosure provides pharmaceutical compositions and methods thereof for the treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. | 2022-08-25 |
20220265741 | Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties - Novel engineered oncolytic protoparvoviruses are described to be used in cancer therapy. The engineered protoparvoviruses contain at least one deletion in the untranslated region and a silencer sequence that remains stably integrated into the viral genome during extensive virus propagation. The novel viruses can be used for the silencing of relevant cancer-related genes, providing to the virus a new anticancer mechanism of action. | 2022-08-25 |
20220265742 | NANO-DISPERSION METHODS FOR CANNABIS EXTRACT - The present disclosure provides techniques for producing whey protein nano-emulsions from | 2022-08-25 |
20220265743 | PROTEIN BASED CANNABIS COMPOSITIONS - Described herein are novel compositions comprising a cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein. | 2022-08-25 |
20220265744 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING - The present invention provides for methods of obtaining an extract of | 2022-08-25 |
20220265745 | Methods of Extraction of Plant Materials and Extracts Obtained Using Supercritical Glycerin - A method for extracting bioactive compounds from plant materials using supercritical glycerin and at least one inert co-solvent that lowers the effective supercritical point of the supercritical glycerin to its boiling point, and the extracts obtained from the method. | 2022-08-25 |
20220265746 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION - Methods for treating coronavirus infection, such as an infection caused by SARS-Cov-2 or MERS-Cov, in a subject in need thereof include administering to the subject a therapeutically effective amount of a composition comprising cnicin. Compositions comprising cnicin include an extract of | 2022-08-25 |
20220265747 | Compositions, Methods, and Medical Compositions for Treatment of and Maintaining the Health of the Liver - Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one | 2022-08-25 |
20220265748 | Liver Activation Nanoemulsion, Solid Binding Composition, and Toxin Excretion Enhancement - An intra-oral, nanoemulsion blend is provided that enhances liver and toxin excretion performance in mammals when orally administered. A solid powder toxin binding composition also is provided that may be used to irreversibly bind the toxins reaching the bowel so that once the toxins are excreted into the bowel, they may not be reabsorbed, and are thus eliminated. A method of administering the nanoemulsion blend and the toxin binding composition to enhance toxin excretion also is described. The nanoemulsion blend is ingestible and edible. | 2022-08-25 |
20220265749 | PREPARATION COMPRISING OMEGA-3 FATTY ACID SALTS AND EXTRACTS OF GUM RESINS FROM BOSWELLIA SPECIES - Preparations may include at least one extract of gum resins from | 2022-08-25 |
20220265750 | COMPOSITION FOR TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONS - The present disclosure provides for a hydrogel formulation comprising a therapeutically effective amount of an extract of the | 2022-08-25 |
20220265751 | COMPOSITION FOR INHIBITING NERVE CELL INJURY CAUSED BY A - The problem to be solved by this invention is to provide a composition for inhibiting nerve cell injury caused by Aβ. This problem is solved by a composition for inhibiting nerve cell injury caused by Aβ, comprising a Kampo extract that contains a | 2022-08-25 |
20220265752 | FOOD SUPPLEMENT, FOR AS ADJUVANT, FOR PREVENTING VASCULAR DEMENTIA - Association comprising: dry extract of | 2022-08-25 |
20220265753 | COMPOSITION FOR ALLEVIATING SYMPTOMS OF ANDROPAUSE, CONTAINING EXTRACT OF FICUS AURICULATA LOUR. AS ACTIVE INGREDIENT - The present invention relates to a method of preventing or alleviating symptoms of andropause comprising administering a pharmaceutically effective amount of an extract of | 2022-08-25 |
20220265754 | METHOD OF IMPROVING DISEASES USING TRADITIONAL CHINESE MEDICINE POLYSACCHARIDES AND BACTERIAL COMPOSITION THEREOF - The present invention provides a method of improving chronic obstructive pulmonary disease and obesity using traditional Chinese medicine polysaccharides and bacterial composition thereof. | 2022-08-25 |
20220265755 | ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION - The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods. In some embodiments the addiction is an addiction to smoking, alcohol and/or drugs. | 2022-08-25 |
20220265756 | ANTIBACTERIAL COMPOSITION EFFECTIVE IN TREATING GRAM NEGATIVE BACTERIAL INFECTIONS AND METHOD FOR PREPARING THE SAME - A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed. | 2022-08-25 |
20220265757 | HEMOSTATIC COMPOSITION AND HEMOSTATIC METHOD USING HEMOSTATIC COMPOSITION - [Problem to be Solved]
| 2022-08-25 |
20220265758 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS - This disclosure provides methods of treating a cancer in a patient using a peptide epoxyketone proteasome inhibitor in combination with a PIM kinase inhibitor. | 2022-08-25 |
20220265759 | COMPOSITION AND METHOD FOR PROMOTING WOUND HEALING - A novel peptide targeting CCR10-eNOS binding is provided as is a cell-permeable construct and method of using the construct to promote or accelerate wound healing, particularly diabetic wound healing. | 2022-08-25 |
20220265760 | LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER - Compositions and methods for suppressing ovarian function in subjects with hormone receptor-positive breast cancer. | 2022-08-25 |
20220265761 | PEPTIDES AND METHODS OF USING THE SAME - Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation. | 2022-08-25 |
20220265762 | COMPOSITION, COMPRISING TMEM176B OR AN EXPRESSION OR ACTIVITY REGULATOR THEREOF AS AN ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASE - This application relates to a composition for prophylaxis or treatment of a neurodegenerative brain disease, the composition including TMEM176B as an active ingredient. In one aspect, the composition not only promotes phagocytosis of amyloid-beta in astrocytes and reduces amyloid plaques, but also exhibits an effect of ameliorating behavior and cognitive functions in an animal model having Alzheimer's disease. Therefore, the composition can be usefully utilized for the prophylaxis and/or treatment of various neurodegenerative brain diseases. | 2022-08-25 |
20220265763 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF - The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided. | 2022-08-25 |
20220265764 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2022-08-25 |
20220265765 | C3 FUSION PROTEIN AND METHODS OF MAKING AND USING THEREOF - The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair. | 2022-08-25 |
20220265766 | ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES - A method of antibiotic treatment combines a pore-forming agent with histones, which stabilize the pores and inhibit transcription. This combination has a significant and complete effect on eliminating bacterial growth. A composition comprising a pore-forming agent and a histone, and optionally, a pharmaceutically acceptable carrier or excipient. The pore-forming agents can include LL-37, magainin, or polymyxin B. Examples of a histone include H2A and H3. A method for killing bacteria comprises contacting bacteria with a pore-forming agent and a histone, or with a composition of the invention. Also provided is a method for treating a bacterial infection in a subject, the method comprising administering a pore-forming agent and a histone to the subject, such as in the form of a composition of the invention. In some embodiments, the bacteria comprise | 2022-08-25 |
20220265767 | HIGH CONCENTRATION CELL PENETRATING CASPASE INHIBITOR CONJUGATES, COMPOSITIONS AND METHODS THEREOF - A method of providing a high concentration disulfide-linked caspase inhibitor-cell penetrating peptide conjugate is described. The method includes incubating a caspase inhibitor having one or more thiol groups with a reducing agent selected from dithiothreitol (DTT), 2-mercaptoethanol (2-ME) and tris(2-carboxyethyl)phosphine (TCEP) to provide a reduced caspase inhibitor, removing the reducing agent from the reduced caspase inhibitor, and conjugating the reduced caspase inhibitor with a cell-penetrating peptide by a disulfide linkage. | 2022-08-25 |
20220265768 | METHODS OF BOOSTING THYMIC REGENERATION IN PATIENTS SUFFERING FROM A THYMIC INJURY BY USING RANKL - Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoiesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, the inventors show that administration of RANK ligand (RANKL) after total body irradiation and BMT boosts thymic regeneration. Notably, this treatment is also beneficial upon BMT in aged individuals. The inventors show that RANKL can improve thymopoiesis in aged individuals affected by thymic involution. Finally, the inventors show that RANK receptor is conserved in the human thymus. Accordingly, one aspect of the present invention relates to a method of boosting thymic regeneration in a patient suffering from a thymic injury comprising administering to the subject a therapeutically effective amount of a RANKL polypeptide. | 2022-08-25 |
20220265769 | COMPOSITIONS AND METHODS OF TREATMENT FOR BREAST CANCER INVOLVING A NOVEL CAPER?-MLL1 COMPLEX - The present invention relates to epigenetic therapies for the treatment of cancer. In particular embodiments, the present invention relates to CAPERα (Coactivator of AP1 and Estrogen Receptor) RRM3 domain-derived cell penetrating peptides that decrease breast cancer growth and survival yet are nontoxic to normal cells. In addition, the present invention relates to nucleic acid molecules encoding such therapeutic peptides, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods of producing the therapeutic peptides of the invention, and to methods of using these therapeutic peptides in the treatment of disease. | 2022-08-25 |
20220265770 | TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN - The invention relates to methods and compositions for treating a neurodegenerative disease. More particularly, the present invention is directed to methods of treatment of neurodegenerative diseases using progranulin and progranulin polypeptides, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression. | 2022-08-25 |
20220265771 | FUSION PROTEIN OF ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - Provided is a fusion protein of an ETA antibody and a TGF-β Trap. Also provided is a pharmaceutical composition of the fusion protein of the ETA antibody and the TGF-β Trap. Further provided is a method for treating, preventing, or improving one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension, pulmonary fibrosis, or cardiovascular fibrosis by using the fusion protein of the ETA antibody and the TGF-β Trap. | 2022-08-25 |
20220265772 | USES OF DAN FAMILY BMP ANTAGONISTS FOR INHIBITING OCULAR NEOVASCULARIZATION AND TREATING OCULAR CONDITIONS - Described herein are methods and pharmaceutical compositions for the prevention and/or treatment of visual impairment and vision loss, and more particularly to the use of DAN family BMP antagonist(s) for the prevention of ocular neovascularization and, as a trophic factor for photoreceptors in eye diseases. Also described is a method for long-term inhibition of neovascularization in an ocular condition, a method of replacement therapy for vascular endothelial growth factor (VEGF) inhibitor treatment and a method for inhibiting and/or preventing ocular neovascularization and/or ocular angiogenesis in a mammalian subject, the methods comprising administering to a mammalian subject in need an effective amount a DAN family BMP antagonist such as DAND5. | 2022-08-25 |
20220265773 | METHODS AND COMPOSITIONS FOR TREATING ARTHRITIS - Methods for treating a subject for arthritis are provided. Aspects of the methods include administration to the subject a rs419598/rs315952/rs9005-haplotype-informed therapeutic regimen. In some instances, the methods include administering to the subject a therapeutic regimen that antagonizes interleukin-1 (IL-1) activity and/or a disease modifying osteoarthritis drug (DMOAD) if the subject has been identified as having a TTG rs419598/rs315952/rs9005 haplotype. Also provided are compositions for use in practicing the methods. | 2022-08-25 |
20220265774 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF - The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides. | 2022-08-25 |
20220265775 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION - A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes an active agent effective to increase T3 concentration in the lung of the subject and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The active agent can include a deiodinase inhibitor, a thyroid hormone mimetic, or a thyroid hormone analog. In some embodiments, the composition can include an additional active agent. The compositions can be used to treat lung inflammation. In some embodiments, the compositions also can be used to treat pulmonary edema. The compositions can be administered to a subject by direct instillation to the pulmonary tract or inhalation directly to the pulmonary tract. | 2022-08-25 |
20220265776 | COMBINATION - The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator, and (ii) an aldosterone antagonist, for instance a combination comprising (a) glibenclamide, or a structural or functional analogue thereof; and (b) at least one of the following components: (i) exenatide, or a structural or functional analogue thereof, or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate, or a structural or functional analogue thereof. Said combinations are suitable for the treatment of stroke and other neurodegenerative disorders and for treating and/or preventing ischemia and/or reperfusion injury in various vital organs, including the brain and the heart. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same. | 2022-08-25 |
20220265777 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID - The invention relates to solid pharmaceutical compositions comprising a GLP-1 agonist, an SGLT2 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine. | 2022-08-25 |
20220265778 | METHOD OF TREATING PARKINSON'S DISEASE WITH INTRANASAL DELIVERY OF INSULIN AND GLUTATHIONE - A method for treating Parkinson's disease where insulin and GSH may be administered intranasally. The GSH and insulin that is administered may be in varying doses at least once daily. The GSH and insulin may be administered sequentially and/or simultaneously and the medications may be administered for differing periods of time depending upon a patient's tolerance and response to the GSH and insulin. The GSH and the insulin may be administered for a certain period of time and/or indefinitely. | 2022-08-25 |
20220265779 | ENHANCEMENT OF SKELETAL MUSCLE STEM CELL ENGRAFTMENT BY DUAL DELIVERY OF VEGF AND IGF-1 - An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time. | 2022-08-25 |
20220265780 | FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF - The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 2022-08-25 |
20220265781 | METHODS FOR INDUCING FULL ABLATION OF HEMATOPOIESIS - The inventors have identified an autosomal dominant (AD) missense mutation in the RAC2 gene (coding for Ras-related botulinum toxin substrate 2 (RAC2)) in three Severe combined immunodeficiencies (SCID) patients whose clinical presentation overlaps with the RD SCID form but who lack AK2 mutations and deafness. Using biochemical and in vitro differentiation assays, the inventors demonstrated that the RAC2 mutation was closely related to an impairment in cell differentiation capacity and defects in cellular and mitochondrial networks. Taken as a whole, the data demonstrate that a dominant gain-of-function (GOF) mutation in the RAC2 protein's GDP/GTP binding site inhibits HSPC differentiation and leads to a severe AD form of SCID with a clinical presentation of RD. Accordingly, the results prompt to consider that introduction of the identified RAC2 mutein in the hematopoietic lineage would be suitable for inducing full ablation of hematopoiesis. | 2022-08-25 |
20220265782 | STABILIZING THERAPEUTIC PROTEINS WITH PIPERAZIN- OR MORPHOLINE-CONTAINING ZWITTERIONIC BUFFERING SUBSTANCES - The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant | 2022-08-25 |
20220265783 | VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE AND/OR AMPHINASE - The present specification discloses Ranpirnase and Amphinase, compositions comprising Ranpirnase and/or Amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFκB pathway signal using Ranpirnase, Amphinase or compositions comprising Ranpirnase and/or Amphinase. | 2022-08-25 |
20220265784 | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF - Featured are pharmaceutical compositions that include a soluble alkaline phosphatase for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP). | 2022-08-25 |
20220265785 | COMPOSITION FOR PREVENTING OR TREATING URIC ACID-RELATED DISEASE - Disclosed in the present invention is use of lysozyme in the preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, and a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid and promoting uric acid excretion. | 2022-08-25 |
20220265786 | METHODS OF IMPROVING ORGAN FUNCTION - Described herein are methods for improving long-term allograft survival and long-term kidney function in subjects that have undergone kidney transplant. An effective amount of one or more complement component 1 esterase inhibitors is administered to the subject, resulting in long-term improvement on kidney allograft survival and function. | 2022-08-25 |
20220265787 | COMPOSITION FOR PROMOTING GROWTH OR SUPPRESSING DECREASE OF MESENCHYMAL STEM CELLS - The present disclosure includes a composition for promoting growth or suppressing decrease of mesenchymal stem cells comprising serpin A3. | 2022-08-25 |
20220265788 | AQUEOUS SOLUTION COMPOSITIONS FOR INCREASING STABILITY OF ENGINEERED DIMERIC PROTEINS - The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein. | 2022-08-25 |
20220265789 | ANTIGENS FOR DETECTING TOXOPLASMA INFECTION BY MONITORING CELLULAR IMMUNITY - Antigens of | 2022-08-25 |
20220265790 | Sea Lice Vaccine - The present invention describes vaccine compositions for treatment and/or prevention against sea lice infestation in salmon. The present invention further describes nucleic acids, host cells, vectors and methods of using said vaccine for the prevention and/or treatment of sea lice infestation in salmon. | 2022-08-25 |
20220265791 | TARGET PEPTIDES FOR CANCER THERAPY AND DIAGNOSTICS - Provided are compositions that include one or more synthetic target peptides, wherein each synthetic target peptide is about or at least 8-50 amino acids long; and has an amino acid sequence as set forth in Table 2 and/or Table 3. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro population of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically binds to a complex of an MHC class I molecule and a peptide having an amino acid sequence as set forth in Table 2 and/or Table 3, methods for treating and/or preventing cancers by administering a therapeutically effective dose of a composition that includes at least one target peptide having an amino acid sequence as set forth in Table 2 and/or Table 3. | 2022-08-25 |
20220265792 | METHODS FOR TREATING SOLID TUMORS - Solid cancerous tumors are treated by administration of an antigen presenting cell agent, a T-cell activating neoantigen vaccine, and an immunosuppression inhibitor. Another aspect of the invention is a method for treating solid cancerous tumors (SCT) in a subject, by administering an antigen presenting cell agent; a T-cell activating vaccine; and an immunosuppression inhibitor. | 2022-08-25 |